228 related articles for article (PubMed ID: 26555266)
1. The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues.
Gettins PG; Dolmer K
J Biol Chem; 2016 Jan; 291(2):800-12. PubMed ID: 26555266
[TBL] [Abstract][Full Text] [Related]
2. High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207.
Migliorini M; Li SH; Zhou A; Emal CD; Lawrence DA; Strickland DK
J Biol Chem; 2020 Jan; 295(1):212-222. PubMed ID: 31792055
[TBL] [Abstract][Full Text] [Related]
3. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
[TBL] [Abstract][Full Text] [Related]
4. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
5. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
6. Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1.
Jensen JK; Dolmer K; Gettins PG
J Biol Chem; 2009 Jul; 284(27):17989-97. PubMed ID: 19439404
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
8. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.
Jensen JK; Malmendal A; Schiøtt B; Skeldal S; Pedersen KE; Celik L; Nielsen NC; Andreasen PA; Wind T
Biochem J; 2006 Nov; 399(3):387-96. PubMed ID: 16813566
[TBL] [Abstract][Full Text] [Related]
10. Quantitative dissection of the binding contributions of ligand lysines of the receptor-associated protein (RAP) to the low density lipoprotein receptor-related protein (LRP1).
Dolmer K; Campos A; Gettins PG
J Biol Chem; 2013 Aug; 288(33):24081-90. PubMed ID: 23798683
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein.
Stefansson S; Muhammad S; Cheng XF; Battey FD; Strickland DK; Lawrence DA
J Biol Chem; 1998 Mar; 273(11):6358-66. PubMed ID: 9497365
[TBL] [Abstract][Full Text] [Related]
13. The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein.
Croucher D; Saunders DN; Ranson M
J Biol Chem; 2006 Apr; 281(15):10206-13. PubMed ID: 16459332
[TBL] [Abstract][Full Text] [Related]
14. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.
Croucher DR; Saunders DN; Stillfried GE; Ranson M
Biochem J; 2007 Dec; 408(2):203-10. PubMed ID: 17696882
[TBL] [Abstract][Full Text] [Related]
15. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
Egelund R; Petersen TE; Andreasen PA
Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
[TBL] [Abstract][Full Text] [Related]
16. Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells.
Roy A; Coum A; Marinescu VD; Põlajeva J; Smits A; Nelander S; Uhrbom L; Westermark B; Forsberg-Nilsson K; Pontén F; Tchougounova E
Oncotarget; 2015 Sep; 6(27):23647-61. PubMed ID: 26164207
[TBL] [Abstract][Full Text] [Related]
17. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein.
Kasza A; Petersen HH; Heegaard CW; Oka K; Christensen A; Dubin A; Chan L; Andreasen PA
Eur J Biochem; 1997 Sep; 248(2):270-81. PubMed ID: 9346278
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2.
Stefansson S; Lawrence DA; Argraves WS
J Biol Chem; 1996 Apr; 271(14):8215-20. PubMed ID: 8626514
[TBL] [Abstract][Full Text] [Related]
19. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
20. The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity.
Bijnens AP; Gils A; Stassen JM; Komissarov AA; Knockaert I; Brouwers E; Shore JD; Declerck PJ
J Biol Chem; 2001 Nov; 276(48):44912-8. PubMed ID: 11559698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
